Sveriges mest populära poddar
GRACEcast Pancreatic Cancer Audio
Hälsa och motionMedicin

Is nindetanib a new agent worthy of becoming a new treatment for advanced NSCLC?

6 min•19 juni 2013

Dr. Nate Pennell from Cleveland Clinic reviews the LUME Lung-1 trial presented by Reck at ASCO 2013, of Taxotere with or without nindetanib (BIBF-1120), an anti-angiogenic multikinase inhibitor, in advanced NSCLC.

Fler avsnitt av GRACEcast Pancreatic Cancer Audio

Visa alla avsnitt av GRACEcast Pancreatic Cancer Audio
Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy?
•5 min
Management of Rare Kidney Tumors
•2 min
Should All Small Cell Lung Cancer Patients Receive Prophylactic Cranial Irradiation?
•5 min
NanoString Treatment for Kidney Cancer
•2 min
Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer?
•2 min
How is the Heng Criteria Applied to Kidney Cancer Patients?
•5 min
Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?
•7 min
What is PD1 and PDL1 in Kidney Cancer?
•3 min
Zykadia for ALK Positive Lung Cancer: New Drug, New Hope
•7 min
No Clear Answer for Non-Clear Cell Kidney Cancer
•6 min

GRACEcast Pancreatic Cancer Audio med cancerGRACE - H. Jack West, MD finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.